{"id":666332,"date":"2023-09-05T16:34:02","date_gmt":"2023-09-05T16:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666332"},"modified":"2023-09-05T16:34:02","modified_gmt":"2023-09-05T16:34:02","slug":"graftversushost-disease-gvhd-market-analysis-of-epidemiology-pipeline-products-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graftversushost-disease-gvhd-market-analysis-of-epidemiology-pipeline-products-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics_666332.html","title":{"rendered":"Graft-versus-host disease (GVHD) Market: Analysis of Epidemiology, Pipeline Products, & Key Companies Working in the Market | Companies – CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics"},"content":{"rendered":"
\n
\"Graft-versus-host<\/a><\/div>\n
\n
Graft Versus Host Disease Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Graft Versus Host Disease (GvHD), historical and forecasted epidemiology as well as the Graft Versus Host Disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Graft-versus-host disease – Market Insights, Epidemiology, and Market Forecast-2032<\/strong><\/a>”.<\/p>\n

Some of the key facts of the Graft-versus-host disease Market Report<\/a>:<\/strong><\/p>\n

    \n
  1. In 2020, the seven major countries reported 24,049 allogeneic cases, with a CAGR projecting an increased number of cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage of all allo-HSCT in the 7MM.<\/li>\n
  2. GvHD is categorized into two types: aGvHD and cGvHD. In the 7MM, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854 in the year 2020, which is expected to rise during the forecast period. <\/li>\n
  3. Germany has the highest number of GvHD cases by type (acute and chronic) among the EU-5 nations, with 2,984 cases in 2020. <\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. The Graft-versus-host disease market report covers a descriptive overview and comprehensive insight of the Graft-versus-host disease Epidemiology and Graft-versus-host disease  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Graft-versus-host disease market report provides insights on the current and emerging therapies.<\/li>\n
    3. Graft-versus-host disease market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Graft-versus-host disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft-versus-host disease market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Graft-versus-host disease Market Landscape<\/a>.<\/strong><\/p>\n

      Graft-versus-host disease Overview<\/strong><\/p>\n

      Graft-versus-host disease is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).<\/p>\n

      The two main types of Graft-versus-host disease are acute Graft-versus-host disease and chronic Graft-versus-host disease. Other than this, Graft-versus-host disease is classified into other types, namely: classic acute Graft-versus-host disease, persistent, recurrent, late-onset acute Graft-versus-host disease, classic chronic Graft-versus-host disease, and overlap syndrome, and de novo chronic Graft-versus-host disease. Patients who get acute Graft-versus-host disease have a 50% chance of developing chronic Graft-versus-host disease.<\/p>\n

      Graft-versus-host disease Market <\/strong><\/p>\n

      The dynamics of the Graft-versus-host disease market<\/strong><\/a> are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Corporation<\/strong>, and others during the forecasted period 2019-2032.<\/p>\n

      Graft-versus-host disease Pipeline Therapies and Key Companies <\/strong><\/p>\n

        \n
      1. CSL 964 AAT (Zemaira): CSL Behring <\/li>\n
      2. Obnitix: Medac<\/li>\n
      3. Leukotac (Inolimomab): ElsaLys Biotech<\/li>\n
      4. KD025 (Belumosudil): Kadmon Therapeutics<\/li>\n
      5. Itacitinib: Incyte Corporation<\/li>\n<\/ol>\n

        Graft-versus-host disease Market Drivers<\/strong><\/p>\n

          \n
        1. Increased participation in clinical trials along with novel strategies<\/li>\n
        2. The rise in the number of cases of allogeneic stem cell transplant<\/li>\n<\/ol>\n

          Table of Contents<\/strong><\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Graft-versus-host disease Patient Share (%) Overview at a Glance<\/p>\n

          5. Graft-versus-host disease Market Overview at a Glance<\/p>\n

          6. Graft-versus-host disease Disease Background and Overview<\/p>\n

          7. Graft-versus-host disease Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Graft-versus-host disease <\/p>\n

          9. Graft-versus-host disease Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Graft-versus-host disease Emerging Therapies<\/p>\n

          12. Graft-versus-host disease Market Outlook<\/p>\n

          13. Country-Wise Graft-versus-host disease Market Analysis (2019–2032)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Graft-versus-host disease Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Click here to read more about Graft-versus-host disease Market Outlook 2032<\/a>.<\/strong><\/p>\n

          Related Reports:<\/strong><\/p>\n

          Graft-versus-host disease Pipeline <\/strong><\/p>\n

          Graft-versus-host disease Epidemiology<\/strong><\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> +91-9650213330
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          Graft Versus Host Disease Market DelveInsight’s “Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Graft Versus Host Disease (GvHD), historical and forecasted epidemiology as well as the Graft Versus Host … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-666332","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=666332"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=666332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=666332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=666332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}